HK Stock Market Move | JD HEALTH (06618) surged more than 4%, with a 14.8% year-on-year growth in revenue in Q3. Operating profit more than doubled.

JD HEALTH(06618) rose over 4%, as of the time of writing, it increased by 4.15%, to 27.6 Hong Kong dollars, with a turnover of 2.28 billion Hong Kong dollars. On the news front, JD HEALTH released its third-quarter financial results for 2024, with revenue of 13.302 billion yuan, a year-on-year increase of 14.8%; operating profit of 552 million yuan, a year-on-year increase of 216%. The company continues to deepen cooperation with pharmaceutical companies, with multiple new drugs launched on JD Pharmacy, including the world's first ultra-long-acting hypoglycemic drug Beilangping under Haisco Pharmaceutical Group, the rare disease drug Fidehr under Novartis Pharmaceuticals, and the lipid-lowering drug Yilietuo under Augilon, etc. During the reporting period, JD HEALTH promoted service innovation by gradually launching online payment services for individual medical accounts in cities such as Guangzhou, Shenzhen, and Chengdu. As of September 30, 2024, the company has provided online medical insurance settlement services in 12 cities, connected nearly 2,000 designated retail pharmacies for medical insurance, and covered a population of over 100 million.